March 26, 2021 -- Twist Bioscience has inked a deal with pharmaceutical company Kyowa Kirin Pharmaceutical Research to develop novel antibodies for therapeutic use against an undisclosed G protein-coupled receptor (GPCR) target molecule.
Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will leverage its unique "library of libraries" for biologics discovery and its proprietary discovery capabilities to discover novel GPCR target-specific antibodies for Kyowa Kirin, the company said in a statement.
Twist received an upfront payment upon signing, while Kyowa Kirin retains an option to obtain development and commercial rights to any antibodies resulting from the agreement, company officials said.
Financial details of the agreement were not disclosed.
Copyright © 2021 scienceboard.net